Opinion|Videos|May 5, 2025
Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options
Author(s)Virginia Kaklamani, MD, DSc, Megan Kruse, MD
Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors.
Advertisement
Episodes in this series
Clinical Brief: Biomarker Testing Strategy in Second-Line Therapy
Main Discussion Topics:
- Strategic approach to biomarker testing when transitioning to second-line therapy
- Importance of liquid biopsy versus tissue biopsy for ESR1 mutation detection
- Role of PIK3CA and other pathway mutations in treatment selection
- Shared decision-making process for selecting between multiple treatment options
- Clinical assessment of endocrine sensitivity duration as a treatment predictor
Key Points for Physicians:
- Liquid biopsy preferred for ESR1 mutation detection due to subclonal nature (15%-20% better detection)
- PIK3CA mutations are clonal and detectable in the initial tissue biopsy
- Prior CDK4/6 inhibitor response duration greater than 12 months indicates endocrine sensitivity
- Multiple treatment options require individualized patient assessment
- Quality-of-life considerations balance with efficacy outcomes
The discussion emphasized that endocrine resistance is a complex phenomenon involving multiple pathways, not just ESR1 mutations, requiring comprehensive biomarker assessment for optimal treatment selection.
Advertisement
Related to this article
Prostate cancer grows slowly, and while 50% of men on active surveillance eventually need treatment, waiting can mean years without side effects.
Liver and bile duct cancer treatment has changed quickly since 2021, with new immunotherapy combinations, targeted pills and a new radiation option. Here's what's been approved and what it means for patients.
Tecentriq plus chemotherapy lowered the risk of cancer returning or death by 50% versus chemotherapy alone in patients with stage 3 dMMR colon cancer.
In the phase 3 MAVERICK trial, people with small cell lung cancer who had regular brain MRIs instead of preventive whole-brain radiation kept their memory and thinking intact longer, with no clear survival difference so far.
In a Johns Hopkins study, 64% of African American patients with myeloma received bone-modifying drugs in their first year, compared with 77% of White patients.
ASTRO’s first bladder cancer radiation guideline supports trimodal therapy as an alternative to bladder removal for select patients with muscle-invasive disease.
The FDA has granted two Breakthrough Therapy Designations to AbbVie's investigational drug Temab-A, one for use in metastatic colorectal cancer and one for non-small cell lung cancer, based on early-phase trial data.
Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.
Advertisement
Advertisement